Calidi Biotherapeutics (CLDI) News Today $0.18 0.00 (0.00%) Closing price 05/22/2026 04:10 PM EasternExtended Trading$0.18 0.00 (-0.46%) As of 05/22/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock CLDI Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Calidi Biotherapeutics, Inc. Issues Financial Statement Audit Report Highlighting Going Concern AssumptionMay 22 at 6:11 PM | quiverquant.comQCalidi Biotherapeutics Provides Required NYSE American DisclosureMay 22 at 6:00 PM | globenewswire.comCalidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVMay 17, 2026 | usatoday.comCalidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational HighlightsMay 14, 2026 | globenewswire.comShort Interest in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Expands By 1,004.7%May 14, 2026 | americanbankingnews.comCalidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in BostonMay 13, 2026 | globenewswire.comCalidi Biotherapeutics Issues Private Placement Warrant FinancingMay 8, 2026 | tipranks.comCalidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AIApril 29, 2026 | globenewswire.comCalidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026April 22, 2026 | markets.businessinsider.comCalidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in ...April 20, 2026 | markets.businessinsider.comCalidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026April 20, 2026 | globenewswire.comCalidi Biotherapeutics to Showcase Advances in Virotherapy at RedChip's Virtual Investor Conference on April 16, 2026April 15, 2026 | quiverquant.comQCalidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic ...April 14, 2026 | markets.businessinsider.comCalidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines ...April 7, 2026 | markets.businessinsider.comCalidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026April 2, 2026 | markets.businessinsider.comCalidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in ...April 1, 2026 | markets.businessinsider.comCalidi Biotherapeutics Reports 2025 Results, Advances Oncology PipelineMarch 30, 2026 | theglobeandmail.comCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational HighlightsMarch 27, 2026 | globenewswire.comCalidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical TrialsMarch 24, 2026 | markets.businessinsider.comCalidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach ...March 12, 2026 | finance.yahoo.comCalidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to ManufacturingMarch 12, 2026 | globenewswire.comCalidi Biotherapeutics Completes Dilutive Public Equity OfferingMarch 11, 2026 | tipranks.comCalidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment OptionMarch 10, 2026 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment OptionMarch 9, 2026 | globenewswire.comCalidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public OfferingMarch 6, 2026 | globenewswire.comCalidi Biotherapeutics (CLDI) stock plunges 35% after hours — here's whyMarch 6, 2026 | msn.comCalidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Proposed Public OfferingMarch 6, 2026 | finanznachrichten.deCalidi Biotherapeutics Announces Proposed Public OfferingMarch 5, 2026 | globenewswire.comCalidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO ConferenceFebruary 20, 2026 | globenewswire.comCalidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO ConferenceFebruary 12, 2026 | globenewswire.comCalidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026January 28, 2026 | markets.businessinsider.comCalidi Biotherapeutics, Inc. Announces Investor Webinar on Novel Genetic Medicine Platform Scheduled for November 19, 2025November 17, 2025 | quiverquant.comQCalidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025November 17, 2025 | globenewswire.comCalidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational HighlightsNovember 13, 2025 | globenewswire.comCalidi presents new data on CLD-401 at 2025 SITC annual meetingNovember 10, 2025 | msn.comCalidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITCNovember 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Unveils New Data on CLD-401November 10, 2025 | msn.comCalidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual MeetingNovember 4, 2025 | markets.businessinsider.comCalidi announces new data to be presented on CLD-401 at 2025 SITC meetingOctober 30, 2025 | msn.comCalidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual MeetingOctober 30, 2025 | markets.businessinsider.comCalidi Biotherapeutics Forms New Advisory BoardOctober 24, 2025 | msn.comCalidi announces formation of its Scientific Advisory BoardOctober 22, 2025 | msn.comCalidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of ...October 22, 2025 | markets.businessinsider.comCalidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in BostonSeptember 29, 2025 | finance.yahoo.comCalidi Biotherapeutics Updates Presentation DisclosureAugust 29, 2025 | tipranks.comCalidi Biotherapeutics (NYSE:CLDI) CEO Eric Poma Buys 25,000 SharesAugust 26, 2025 | insidertrades.comCalidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment OptionAugust 22, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment OptionAugust 21, 2025 | globenewswire.comCalidi prices 1.47M units at $2.00 in underwritten public offeringAugust 20, 2025 | msn.comCalidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public OfferingAugust 20, 2025 | globenewswire.com Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLDI Media Mentions By Week CLDI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDI News Sentiment▼0.480.45▲Average Medical News Sentiment CLDI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDI Articles This Week▼21▲CLDI Articles Average Week Get the Latest News and Ratings for CLDI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Calidi Biotherapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Liminatus Pharma News Today Creative Medical Technology News Today Bullfrog AI News Today NKGen Biotech News Today NuCana News Today Portage Biotech News Today Brainstorm Cell Therapeutics News Today Galera Therapeutics News Today Curative Biotechnology News Today TNF Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:CLDI) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
